Not a good buy right now for an impatient investor: price trend is still bearish (stacked bearish moving averages + MACD below zero) and there are no proprietary buy signals today.
Near-term bounce potential exists because price is sitting near support (~4.15) with a low RSI, but this is a speculative mean-reversion setup, not a confirmed reversal.
With no fresh news catalysts and weak underlying fundamentals (very low revenue, ongoing losses), the risk/reward does not justify chasing at $4.12 today.
Politicians/congress: no recent congress trading data available; no notable insider/hedge fund trend signal provided.
MACD: Histogram -0.0453 (below 0) and negatively contracting—downtrend momentum persists, though selling pressure may be stabilizing.
RSI(6): 33.135—weak/near-oversold zone, suggesting bounce potential but not a confirmed reversal signal.
Key levels: Support S1 ~4.15 (price $4.12 is slightly below/at this area) then S2 ~3.801; Resistance pivot ~4.715 then R1 ~5.281.
Price action context: Regular market +2.11% but pre-market -1.87%—mixed tape and no clear momentum follow-through.
Pattern-based odds: Model suggests +6.87% next week potential, but slightly negative next month (-1.01%), aligning with “short pop within a weak trend.”
Reported put/call ratios are 0.0, which typically indicates missing/thin options data rather than a true sentiment extreme—so options positioning is not a reliable read here.
Volatility: Historical volatility ~71.23% (high), consistent with a small-cap biotech-style name where price can move sharply on catalysts.
Technical Summary
Sell
8
Buy
3
Positive Catalysts
with RSI near oversold—could fuel a short-term reflex bounce if buyers step in.
Neutral/Negative Catalysts
No news in the recent week—no immediate event-driven catalyst to force a re-rating right now.
Technical structure remains bearish (moving-average stack + MACD below zero); rallies can fail into resistance (4.715–5.28 zone).
Options data is not informative (0.0 ratios / missing fields), so there’s no strong derivatives-based confirmation of bullish sentiment.
Business risk profile: ongoing losses and minimal revenue base increase dependency on clinical/regulatory catalysts.
Financial Performance
Latest quarter: 2025/Q3.
Revenue: $15K, down -82.76% YoY (very weak top-line trajectory).
Net income: -$8.777M, improved 9.90% YoY (losses still large).
EPS: -$0.85, down -30.33% YoY (worse per-share performance).
Gross margin: 100 (improved +26.09% YoY), but on a very small revenue base—does not offset operating losses.
Overall: financials look like a pre-commercial/catalyst-dependent profile rather than self-sustaining growth.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
[2025-12-03] Maxim (Naz Rahman): reiterated Buy; raised price target to $30 from $20 on FDA-recommended biomarker analyses and perceived NDA pathway progress.
Trend summary: limited coverage shown (single highlighted update), but the direction is clearly more bullish (target raised).
Wall Street-style pros: strong upside framing tied to regulatory/clinical progress (biomarker results) and potential NDA filing narrative.
Wall Street-style cons: target appears largely catalyst-driven vs. supported by current financial performance; execution/regulatory timing uncertainty remains high.
Wall Street analysts forecast CLNN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CLNN is 30.4 USD with a low forecast of 30 USD and a high forecast of 31 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast CLNN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CLNN is 30.4 USD with a low forecast of 30 USD and a high forecast of 31 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 3.920
Low
30
Averages
30.4
High
31
Current: 3.920
Low
30
Averages
30.4
High
31
Maxim
Naz Rahman
Buy
maintain
$20 -> $30
AI Analysis
2025-12-03
Reason
Maxim
Naz Rahman
Price Target
$20 -> $30
AI Analysis
2025-12-03
maintain
Buy
Reason
Maxim analyst Naz Rahman raised the firm's price target on Clene to $30 from $20 and keeps a Buy rating on the shares after the company and its wholly owned subsidiary Clene Nanomedicine announced completion of the FDA-recommended biomarker analyses for CNM-Au8 in people living with ALS. The results demonstrate statistically significant reductions in both neurofilament light, NfL, and glial fibrillary acidic protein, GFAP, which "clears way" for an NDA filing, the analyst says.
Benchmark
Buy
downgrade
$33 -> $31
2025-09-10
Reason
Benchmark
Price Target
$33 -> $31
2025-09-10
downgrade
Buy
Reason
Benchmark lowered the firm's price target on Clene to $31 from $33 and keeps a Buy rating on the shares. Having obtained agreement from the FDA regarding the statistical analysis plan, Clene continues to work toward an anticipated NDA submission in Q4 for CNM-Au-8 in the treatment of ALS, the analyst noted while updating the firm's model.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CLNN
